Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct;43(10):1078-1085.
doi: 10.1111/pace.14018. Epub 2020 Jul 31.

Safety of bioelectrical impedance analysis in advanced heart failure patients

Luise Roehrich  1   2   3 , Simon Suendermann  2   4 , Isabell Anna Just  1 , Jan Knierim  1 , Johanna Mulzer  1 , Marcus Mueller  1 , Jaime-Juergen Eulert-Grehn  1   2 , Manfred Hummel  5 , Christoph Starck  1   2 , Evgenij Potapov  1   2 , Christoph Knosalla  1   2 , Volkmar Falk  1   2   4   6 , Felix Schoenrath  1   2
Affiliations

Safety of bioelectrical impedance analysis in advanced heart failure patients

Luise Roehrich et al. Pacing Clin Electrophysiol. 2020 Oct.

Abstract

Background: Cardiac cachexia and frailty are major complications of advanced heart failure (AHF). Bioelectrical impedance analysis (BIA) may provide valuable information regarding fluid balance, muscle mass and prognosis. The main concerns regarding the use of BIA in AHF patients remain arrhythmias and electromagnetic interferences with cardiac implantable electronic devices (CIEDs). Reliable data regarding patients on continuous-flow ventricular assist device (cf-VAD) remain scarce. The aim of this study is to evaluate the safety of BIA in AHF patients on pro-arrhythmogenic therapy with an implanted CIED and/or with a cf-VAD.

Methods: We prospectively performed 217 BIA measurements in 143 AHF patients at risk of severe arrhythmias due to inotropic support/a history of ventricular arrhythmias and/or treated with CIED, including 104 patients with an ICD, CRT or pacemaker and 95 patients with a cf-VAD. All patients were under continuous Electrocardiogram (ECG) monitoring and clinical surveillance for 24 hours.

Results: No adverse events were observed during the 217 BIA measurements: No rhythm disturbances were documented in the telemetric monitoring during or within 30 minutes after the measurement. CIEDs showed no malfunction, regardless of the location measured or the device manufacturer. In particular, no inappropriate shocks were observed. No alarms, flow disturbances, or malfunctions of the cf-VAD occurred during or after the measurements.

Conclusion: We consider BIA a safe measurement with major clinical relevance in our cohort of AHF patients, despite an increased arrhythmic potential on inotropic support or the presence of implanted electronic devices (ICD, CRT, pacemaker and cf-VAD).

Keywords: advanced heart failure; bioelectrical impedance analysis; electromagnetic interference; implantable cardiac defibrillator; sarcopenia; ventricular assist device.

PubMed Disclaimer

References

REFERENCES

    1. von Haehling S, Anker SD. Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014. J Cachexia Sarcopenia Muscle. 2014;5:261-263.
    1. Denfeld QE, Winters-Stone K, Mudd JO, Gelow JM, Kurdi S, Lee CS. The prevalence of frailty in heart failure: a systematic review and meta-analysis. Int J Cardiol. 2017;236:283-289.
    1. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48:601.
    1. Saitoh M, Ishida J, Doehner W, et al. Sarcopenia, cachexia, and muscle performance in heart failure: review update 2016. Int J Cardiol. 2017;238:5-11.
    1. Musci M, Loforte A, Potapov EV, et al. Body mass index and outcome after ventricular assist device placement. Ann Thorac Surg. 2008;86:1236-1242.